About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR

Company Statement

Biocon Update on Insulin Glargine

Bengaluru, India, June 02, 2018

"Following submission of our Insulin Glargine application under the 505(b)(2) regulatory pathway, we had agreed with the US FDA to provide additional clinical data in support of the manufacturing site change from Bangalore to Malaysia. Hence, the recent CRL was anticipated and built into our plan. Together, Mylan and Biocon are already executing on all required activities we had agreed upon with FDA, and they are progressing according to plan. We do not anticipate any impact to the previously communicated timing of approval and anticipated launch by our partner Mylan." - Company Spokesperson

<< Back




Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved